{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:53:32Z","timestamp":1791287612629,"version":"4.1.0"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>While lysine acetyltransferase 6A (KAT6A; MOZ\/MYST3) and 6B (KAT6B; MORF\/MYST4) function as context-dependent oncogenic drivers\u2014with KAT6B also displaying tissue-specific tumor-suppressive roles\u2014their pharmacological targeting holds promise as a therapeutic avenue. This conceptual and translational review synthesizes evidence from genetic depletion models, pharmacological catalytic inhibitors, and emerging proteolysis-targeting chimera (PROTAC) degraders, introducing the \u201cDual-Compartment Hypothesis\u201d as a conceptual interpretive framework to organize current evidence and generate testable hypotheses regarding their putative impacts on the tumor immune microenvironment (TIME). Under this framework, KAT6A\/B blockade within the primary tumor compartment is proposed to indirectly foster regional antitumor immunity via preclinically implicated pathways, including tumor cell ferroptosis, cyclic GMP-AMP synthase\u2013stimulator of interferon genes (cGAS-STING) activation, and interleukin-6 (IL-6) suppression, alongside putative downstream influences on immune checkpoints. In contrast, systemic drug exposure in the secondary compartment may directly alter hematopoiesis and lymphocyte development, creating a tension between local immune activation and systemic constraints. Importantly, immune cells within the tumor microenvironment may also be directly suppressed by KAT6A\/B inhibition\u2014an alternative outcome that remains to be systematically investigated. Resolving these divergent outcomes necessitates distinguishing genetic knockout\/knockdown (KO\/KD) from pharmacological inhibition or degradation\u2014a distinction that is critical because much of the mechanistic evidence derives from genetic models, while accounting for KAT6A versus KAT6B isoform selectivity. Finally, we outline testable translational frameworks, such as intermittent dosing schedules and rational immunotherapeutic combinations, to direct subsequent experimental and clinical validation, while acknowledging that current early-phase clinical observations (objective response rate [ORR]\/clinical benefit rate [CBR]) reflect composite therapeutic responses and require further paired biomarker validation to definitively isolate immune-mediated effects.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1961903","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:19:00Z","timestamp":1791285540000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting lysine acetyltransferase 6A\/B in cancer: a conceptual and translational review of epigenetic regulation, immune microenvironment remodeling, and the dual-compartment hypothesis"],"prefix":"10.3389","volume":"17","author":[{"given":"Cong","family":"Ma","sequence":"first","affiliation":[{"name":"Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingru","family":"Wang","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhua","family":"Qiao","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhong","family":"Wu","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zheng","sequence":"additional","affiliation":[{"name":"Breast Cancer Center, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-0296","article-title":"The epigenetic hallmarks of cancer","volume":"14","author":"Esteller","year":"2024","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s10565-024-09984-0","article-title":"The important role of the histone acetyltransferases p300\/CBP in cancer and the promising anticancer effects of p300\/CBP inhibitors","volume":"41","author":"Wu","year":"2025","journal-title":"Cell Biol Toxicol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2760","article-title":"Pan-cancer patterns of somatic copy number alteration","volume":"45","author":"Zack","year":"2013","journal-title":"Nat Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m602633200","article-title":"MOZ-TIF2 alters cofactor recruitment and histone modification at the RARbeta2 promoter: differential effects of MOZ fusion proteins on CBP- and MOZ-dependent activators","volume":"281","author":"Collins","year":"2006","journal-title":"J Biol Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105930","article-title":"The role of MOZ\/KAT6A in hematological malignancies and advances in MOZ\/KAT6A inhibitors","volume":"174","author":"Su","year":"2021","journal-title":"Pharmacol Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02613","article-title":"Targeting KAT6A\/B as a new therapeutic strategy for cancer therapy","volume":"68","author":"Zheng","year":"2025","journal-title":"J Med Chem"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2014.07.007","article-title":"KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer","volume":"16","author":"Turner-Ivey","year":"2014","journal-title":"Neoplasia (New York NY)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0238477","article-title":"KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma","volume":"15","author":"Saglam","year":"2020","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0191-7","article-title":"NEAT1-TFE3 and KAT6A-TFE3 renal cell carcinomas, new members of MiT family translocation renal cell carcinoma","volume":"32","author":"Pei","year":"2019","journal-title":"Modern Pathol Off J United States Can Acad Pathology Inc"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1182\/blood-2024-208358","article-title":"Oncogenic potential and sensitivity to Menin inhibitors of a novel fusion KAT6B::NUTM2B in congenital myeloid sarcoma with bone marrow involvement","volume":"144","author":"Voss","year":"2024","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"26935","DOI":"10.1038\/s41598-024-78432-0","article-title":"ER\u03b1 status of invasive ductal breast carcinoma as a result of regulatory interactions between lysine deacetylases KAT6A and KAT6B","volume":"14","author":"Olbromski","year":"2024","journal-title":"Sci Rep"},{"key":"B13","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13046-018-0834-z","article-title":"miR-22\/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma","volume":"37","author":"Gu","year":"2018","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70520","article-title":"Lysine acetyltransferase 6 in health and disease","volume":"6","author":"Tan","year":"2025","journal-title":"MedComm"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03060-0","article-title":"Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial","volume":"30","author":"Mukohara","year":"2024","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-lb166","article-title":"Abstract LB166: OP-3136, a selective KAT6 inhibitor, demonstrates anti-tumor activity in prostate, ovarian, and non-small cell lung cancer preclinical models","volume":"85","author":"Palanisamy","year":"2025","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12885-025-15368-2","article-title":"Histone acetyltransferase KAT6A contributes to colon cancer malignant progression by inhibiting ferroptosis","volume":"26","author":"Huo","year":"2025","journal-title":"BMC Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217946","article-title":"Inhibition of KAT6A enhances immunotherapy efficacy in colorectal cancer by activating interferon response","volume":"631","author":"Han","year":"2025","journal-title":"Cancer Lett"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202400140","article-title":"KAT6A condensates impair PARP1 trapping of PARP inhibitors in ovarian cancer","volume":"11","author":"Zhan","year":"2024","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018762","article-title":"Writers and readers of histone acetylation: structure, mechanism, and inhibition","volume":"6","author":"Marmorstein","year":"2014","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2012.10.004","article-title":"Tandem PHD fingers of MORF\/MOZ acetyltransferases display selectivity for acetylated histone H3 and are required for the association with chromatin","volume":"424","author":"Ali","year":"2012","journal-title":"J Mol Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt931","article-title":"The double PHD finger domain of MOZ\/MYST3 induces \u03b1-helical structure of the histone H3 tail to facilitate acetylation and methylation sampling and modification","volume":"42","author":"Dreveny","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.01297-08","article-title":"Molecular architecture of quartet MOZ\/MORF histone acetyltransferase complexes","volume":"28","author":"Ullah","year":"2008","journal-title":"Mol Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003490","article-title":"MOZ is critical for the development of MOZ\/MLL fusion-induced leukemia through regulation of Hoxa9\/Meis1 expression","volume":"6","author":"Katsumoto","year":"2022","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14174068","article-title":"BRPF1-KAT6A\/KAT6B complex: molecular structure, biological function and human disease","volume":"14","author":"Zu","year":"2022","journal-title":"Cancers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01426","article-title":"Biological activity and structural biology of current KAT6A inhibitor chemotypes","volume":"69","author":"Suwandi","year":"2026","journal-title":"J Med Chem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-70574-1","article-title":"Hierarchical small molecule inhibition of MYST acetyltransferases","volume":"17","author":"Chen","year":"2026","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115770","article-title":"Discovery of N-(2-oxoethyl) sulfanilamide-derived inhibitors of KAT6A (MOZ) against leukemia by an isostere strategy","volume":"260","author":"Duan","year":"2023","journal-title":"Eur J Med Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00665","article-title":"Discovery of benzoylsulfonohydrazides as potent inhibitors of the histone acetyltransferase KAT6A","volume":"62","author":"Leaver","year":"2019","journal-title":"J Med Chem"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0387-5","article-title":"Inhibitors of histone acetyltransferases KAT6A\/B induce senescence and arrest tumour growth","volume":"560","author":"Baell","year":"2018","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b02071","article-title":"Discovery of acylsulfonohydrazide-derived inhibitors of the lysine acetyltransferase, KAT6A, as potent senescence-inducing anti-cancer agents","volume":"63","author":"Priebbenow","year":"2020","journal-title":"J Med Chem"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.chembiol.2023.07.005","article-title":"Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A\/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer","volume":"30","author":"Sharma","year":"2023","journal-title":"Cell Chem Biol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-1772","article-title":"KAT6A and KAT7 histone acetyltransferase complexes are molecular dependencies and therapeutic targets in NUP98-rearranged acute myeloid leukemia","volume":"15","author":"Michmerhuizen","year":"2025","journal-title":"Cancer Discov"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2023.08.006","article-title":"HATS off to KAT6A\/B inhibitors: a new way to target estrogen-receptor-positive breast cancer","volume":"30","author":"Jeselsohn","year":"2023","journal-title":"Cell Chem Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.16_suppl.3006","article-title":"A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+HER2-breast cancer","volume":"42","author":"Mukohara","year":"2024","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.1054","article-title":"First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors","volume":"41","author":"Sommerhalder","year":"2023","journal-title":"J Clin Oncol"},{"key":"B37","article-title":"An interventional, open-label, randomized, multicenter, phase 3 study of PF-07248144 plus fulvestrant compared to investigator's choice of therapy in adult participants with hormone receptor-positive, HER2-negative advanced\/metastatic breast cancer whose disease progressed after prior CDK4\/6 inhibitor-based therapy (NCT07062965)","year":"2026","journal-title":"ClinicalTrialsgov"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.sabcs23-po2-05-08","article-title":"ISM5043, a novel, selective KAT6 inhibitor for the treatment of advanced and refractory ER plus breast cancer","volume":"84","author":"Cai","year":"2024","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-464","article-title":"Discovery and development of IST-477, a selective KAT6A histone acetyl transferase inhibitor and characterization of its anti-tumor efficacy in ER+HER2-breast cancer and other tumor indications","volume":"85","author":"Rai","year":"2025","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2022.107741","article-title":"The synthesis of PROTAC molecule and new target KAT6A identification of CDK9 inhibitor i CDK9","volume":"34","author":"Ao","year":"2023","journal-title":"Chin Chem Lett"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2026-5793","article-title":"First-in-class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved preclinical hematological safety profile","volume":"86","author":"Sivakumar","year":"2026","journal-title":"Am Assoc For Cancer Res (AACR) Annu Meeting 2026"},{"key":"B42","article-title":"Prelude Therapeutics reports second quarter 2026 financial results and provides corporate update","year":"2026","journal-title":"GLOBE NEWSWIRE"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06348-2","article-title":"Rewiring cancer drivers to activate apoptosis","volume":"620","author":"Gourisankar","year":"2023","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.3c04640","article-title":"Acetylation targeting chimera enables acetylation of the tumor suppressor p53","volume":"145","author":"Kabir","year":"2023","journal-title":"J Am Chem Soc"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202401151R","article-title":"Circ_0005397 inhibits ferroptosis of pancreatic cancer cells by up-regulating PCBP2 through KAT6A\/H3K9Ac","volume":"38","author":"Qu","year":"2024","journal-title":"FASEB J Off Publ Fed Am Societies For Exp Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1101\/2025.07.01.662644","article-title":"KAT6A\/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma","author":"Weichert-Leahey","year":"2025","journal-title":"bioRxiv preprint server For Biol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i9.105937","article-title":"Correlation between KAT6A and PD-L1 expression and role of KAT6A in colorectal cancer","volume":"17","author":"Zhou","year":"2025","journal-title":"World J Gastrointestinal Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264014","article-title":"Expression of epigenetic pathway related genes in association with PD-L1, ER\/PgR and MLH1 in endometrial carcinoma","volume":"17","author":"Saglam","year":"2022","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-676072","article-title":"MOZ (KAT6A) is essential for the maintenance of classically defined adult hematopoietic stem cells","volume":"128","author":"Sheikh","year":"2016","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202100014","article-title":"KAT6A acetylation of SMAD3 regulates myeloid-derived suppressor cell recruitment, metastasis, and immunotherapy in triple-negative breast cancer","volume":"8","author":"Yu","year":"2021","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nature07483","article-title":"Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen","volume":"456","author":"Hurtado","year":"2008","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102192","article-title":"Combined inhibition of KAT6A\/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer","volume":"6","author":"Olsen","year":"2025","journal-title":"Cell Rep Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1170-y","article-title":"CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy","volume":"569","author":"Wang","year":"2019","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2026.112496","article-title":"Lipid metabolic reprogramming of CD8(+) T cells in the tumor microenvironment","volume":"143","author":"Mao","year":"2026","journal-title":"Cell Signalling"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-594655","article-title":"MOZ regulates B-cell progenitors and, consequently, Moz haploinsufficiency dramatically retards MYC-induced lymphoma development","volume":"125","author":"Sheikh","year":"2015","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.cmet.2023.12.016","article-title":"Lysine acetyltransferase 6A maintains CD4(+) T cell response via epigenetic reprogramming of glucose metabolism in autoimmunity","volume":"36","author":"Fu","year":"2024","journal-title":"Cell Metab"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00462-0","article-title":"Broadening horizons: the role of ferroptosis in cancer","volume":"18","author":"Chen","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41419-025-08204-9","article-title":"Immune cells dying from ferroptosis: mechanisms and therapeutic opportunities","volume":"16","author":"Liu","year":"2025","journal-title":"Cell Death Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2239","article-title":"ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition","volume":"13","author":"Doll","year":"2017","journal-title":"Nat Chem Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2500092","article-title":"KAT6B may be applied as a potential therapeutic target for glioma","volume":"2022","author":"Liu","year":"2022","journal-title":"J Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2147\/jir.s506964","article-title":"The dual roles of STAT3 in ferroptosis: mechanism, regulation and therapeutic potential","volume":"18","author":"Xie","year":"2025","journal-title":"J Inflammation Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2023.03.003","article-title":"STAT3 signaling promotes cardiac injury by upregulating NCOA4-mediated ferritinophagy and ferroptosis in high-fat-diet fed mice","volume":"201","author":"Zhu","year":"2023","journal-title":"Free Radical Biol Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109737","article-title":"STAT3 drives the expression of ACSL4 in acute kidney injury","volume":"27","author":"Poindessous","year":"2024","journal-title":"iScience"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00439-023-02608-3","article-title":"KAT6A mutations in Arboleda-Tham syndrome drive epigenetic regulation of posterior HOXC cluster","volume":"142","author":"Singh","year":"2023","journal-title":"Hum Genet"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nature10802","article-title":"DNA breaks and chromosome pulverization from errors in mitosis","volume":"482","author":"Crasta","year":"2012","journal-title":"Nature"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/nature23449","article-title":"cGAS surveillance of micronuclei links genome instability to innate immunity","volume":"548","author":"Mackenzie","year":"2017","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-19-0229","article-title":"STING signaling in melanoma cells shapes antigenicity and can promote antitumor T-cell activity","volume":"7","author":"Falahat","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2023.10.003","article-title":"Resveratrol induces major histocompatibility complex class I antigen presentation in a STING-dependent and independent manner in melanoma","volume":"163","author":"Morehead","year":"2023","journal-title":"Mol Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrm.2016.140","article-title":"Metabolic regulation of gene expression through histone acylations","volume":"18","author":"Sabari","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.49","article-title":"YEATS2 is a selective histone crotonylation reader","volume":"26","author":"Zhao","year":"2016","journal-title":"Cell Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Sci (New York NY)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.scib.2025.07.013","article-title":"An IL-6-induced STAT3-to-PI3K signaling switch potently drives PD-L1 transcription in cancer stem cells of colorectal cancer","volume":"71","author":"Tian","year":"2026","journal-title":"Sci Bull (Beijing)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1263412","article-title":"The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200","volume":"6","author":"Noman","year":"2017","journal-title":"Oncoimmunology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13059-025-03743-y","article-title":"KAT6A chimeras form a self-reinforcing epigenetic module with NURF and MLL\/COMPASS to sustain AML","volume":"26","author":"Lv","year":"2025","journal-title":"Genome Biol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-086835","article-title":"Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function","volume":"111","author":"Pan","year":"2008","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2024.195028","article-title":"The essential link: How STAT3 connects tumor metabolism to immunity","volume":"1867","author":"Zhong","year":"2024","journal-title":"Biochim Biophys Acta Gene Regul Mech"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2015.33","article-title":"MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway","volume":"34","author":"Sheikh","year":"2015","journal-title":"Oncogene"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0156-2","article-title":"Unmasking senescence: context-dependent effects of SASP in cancer","volume":"19","author":"Faget","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11762","article-title":"Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis","volume":"7","author":"Ruhland","year":"2016","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70515","article-title":"Immunosenescence: Molecular mechanisms, diseases, and therapeutic innovations","volume":"6","author":"Gong","year":"2025","journal-title":"MedComm"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2025.07.022","article-title":"Immunoregulatory mechanisms in the aging microenvironment: Targeting the senescence-associated secretory phenotype for cancer immunotherapy","volume":"15","author":"Wang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00450-9","article-title":"Exploiting senescence for the treatment of cancer","volume":"22","author":"Wang","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B87","doi-asserted-by":"crossref","DOI":"10.1101\/2025.11.05.684493","article-title":"An InDel genomic variant within a bifunctional super-enhancer for LINC00636 and CD47 regulation in breast cancer","volume-title":"Biorxiv : The Preprint Server for Biology","author":"Di Benedetto","year":"2025"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14802","article-title":"A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer","volume":"8","author":"Betancur","year":"2017","journal-title":"Nat Commun"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1126\/science.aac9935","article-title":"MYC regulates the antitumor immune response through CD47 and PD-L1","volume":"352","author":"Casey","year":"2016","journal-title":"Sci (New York NY)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119438","article-title":"A regulatory loop among CD276, miR-29c-3p, and Myc exists in cancer cells against natural killer cell cytotoxicity","volume":"277","author":"Lee","year":"2021","journal-title":"Life Sci"},{"key":"B91","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/s41419-024-06791-7","article-title":"The miR-29 family facilitates the activation of NK-cell immune responses by targeting the B7-H3 immune checkpoint in neuroblastoma","volume":"15","author":"Pathania","year":"2024","journal-title":"Cell Death Dis"},{"key":"B92","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/2159-8290.cd-20-1459","article-title":"KAT6A and ENL form an epigenetic transcriptional control module to drive critical leukemogenic gene-expression programs","volume":"12","author":"Yan","year":"2022","journal-title":"Cancer Discov"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1261\/rna.7100104","article-title":"Multiple links between transcription and splicing","volume":"10","author":"Kornblihtt","year":"2004","journal-title":"RNA (New York NY)"},{"key":"B94","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41523-025-00858-0","article-title":"Exploring KAT6 as a therapeutic target in breast cancer: epigenetic approaches for precision medicine","volume":"11","author":"Roussel-Simonin","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"B96","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1016\/j.cell.2021.05.038","article-title":"Pharmacologic modulation of RNA splicing enhances anti-tumor immunity","volume":"184","author":"Lu","year":"2021","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B98","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10238-024-01490-1","article-title":"The crossroad between tumor and endothelial cells","volume":"24","author":"Ribatti","year":"2024","journal-title":"Clin Exp Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1549276","article-title":"Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03701-8","article-title":"Targeting tumor vascularization: promising strategies for vascular normalization","volume":"147","author":"Zheng","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13814","article-title":"The interaction between vasculogenic mimicry and the immune system: Mechanistic insights and dual exploration in cancer therapy","volume":"58","author":"Liu","year":"2025","journal-title":"Cell Prolif"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s10565-023-09805-w","article-title":"SNORD17-mediated KAT6B mRNA 2'-O-methylation regulates vasculogenic mimicry in glioblastoma cells","volume":"39","author":"Cui","year":"2023","journal-title":"Cell Biol Toxicol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.08.056","article-title":"Acetylation of the Cd8 locus by KAT6A determines memory T cell diversity","volume":"16","author":"Newman","year":"2016","journal-title":"Cell Rep"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116732","article-title":"Histone acetylation alteration by KAT6A inhibitor WM-1119 suppresses IgE-mediated mast cell activation and allergic inflammation via reduction in AP-1 signaling","volume":"232","author":"Jiao","year":"2025","journal-title":"Biochem Pharmacol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/jcpe.14203","article-title":"KAT6A promotes macrophage inflammation and periodontitis","volume":"52","author":"Huang","year":"2025","journal-title":"J Clin Periodontology"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012976","article-title":"Genetically engineered ErbB2 overexpression sensitizes organoid-derived tumors to checkpoint inhibition in a syngeneic model of gastric cancer","volume":"14","author":"He","year":"2026","journal-title":"J Immunother Cancer"},{"key":"B107","doi-asserted-by":"publisher","first-page":"10983","DOI":"10.1038\/s41467-025-66800-x","article-title":"ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer","volume":"16","author":"Meder","year":"2025","journal-title":"Nat Commun"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.272","article-title":"Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance","volume":"34","author":"Cordo Russo","year":"2015","journal-title":"Oncogene"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.105070","article-title":"The crosstalk between ferroptosis and the immune system in urological cancers: Mechanisms, prognostic value, and therapeutic implications","volume":"218","author":"Li","year":"2026","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.01.010","article-title":"Histone lysine acetyltransferase inhibitors: An emerging class of drugs for cancer therapy","volume":"45","author":"White","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"B111","article-title":"IDEAYA announces development candidate nomination of IDE251, a potential first-in-class KAT6\/7 dual inhibitor targeting 8p11 amplification tumors in breast and lung cancers","year":"2024"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2026-4494","article-title":"Abstract 4494: A highly selective KAT6\/7 dual inhibitor with best-in-class potential and favorable pharmacokinetic profile","volume":"86","author":"Yang","year":"2026","journal-title":"Cancer Res"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.sabcs25-ps1-10-09","article-title":"Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+\/HER2- metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D)","volume":"43","author":"LoRusso","year":"2026","journal-title":"J Clin Oncol"},{"key":"B114","article-title":"Prelude therapeutics presents preclinical data from development candidate, PRT13722, a first-in-class, orally bioavailable, potent and highly selective KAT6A degrader at american association for cancer research (AACR) annual meeting 2026","year":"2026"},{"key":"B115","article-title":"Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics","year":"2024"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2025-368","article-title":"Abstract 368: Unique breast cancer CDX panels for KAT6, ER, and CDK4\/6","volume":"85","author":"Pang","year":"2025","journal-title":"Cancer Res"},{"key":"B117","doi-asserted-by":"publisher","first-page":"CT174","DOI":"10.1158\/1538-7445.AM2026-CT174","article-title":"Abstract CT174: Unlocking endocrine resistance: Co-targeting KAT6 and ER with prifetrastat (PF-07248144) and fulvestrant drives tumor and ctDNA response in ER+\/HER2\u2010 metastatic breast cancer","volume":"86","author":"Layman","year":"2026","journal-title":"Cancer Res"},{"key":"B118","article-title":"A phase 3, randomized, open-label, multicenter study of PF-07248144 in combination with fulvestrant versus investigator's choice of endocrine therapy in participants with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+\/HER2-) advanced or metastatic breast cancer who have progressed on prior CDK4\/6 inhibitor-based regimen (VERITAC-3)","volume-title":"Clinicaltrialsgov","year":"2024"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.2174\/0113895575409206250918080644","article-title":"Breaking barriers in breast cancer: Multi-targeted therapeutic insights","volume":"25","author":"Unni","year":"2025","journal-title":"Mini-Rev Med Chem"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0109-9","article-title":"Epigenetic therapy in immune-oncology","volume":"19","author":"Jones","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Sci (New York NY)"},{"key":"B123","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf2807","article-title":"Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade","volume":"354","author":"Pauken","year":"2016","journal-title":"Sci (New York NY)"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"key":"B126","doi-asserted-by":"publisher","first-page":"108162","DOI":"10.2139\/ssrn.4002401","article-title":"Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs","volume":"235","author":"Walz","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B127","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.ccr-19-1868","article-title":"Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade","volume":"26","author":"House","year":"2020","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf169","article-title":"Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors","volume":"30","author":"Tsimberidou","year":"2025","journal-title":"Oncologist"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-026-04316-6","article-title":"Reprogramming resistance in advanced lung cancer: Epigenetic modulation to restore therapeutic vulnerability","volume":"28","author":"He","year":"2026","journal-title":"Clin Trans Oncol Off Publ Fed Spanish Oncol Societies Natl Cancer Institute Mexico"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2015.04.011","article-title":"Mesodermal expression of Moz is necessary for cardiac septum development","volume":"403","author":"Vanyai","year":"2015","journal-title":"Dev Biol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.exphem.2016.10.006","article-title":"MOZ and BMI1 act synergistically to maintain hematopoietic stem cells","volume":"47","author":"Sheikh","year":"2017","journal-title":"Exp Hematol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12072","article-title":"The MYSTerious MOZ, a histone acetyltransferase with a key role in haematopoiesis","volume":"139","author":"Perez-Campo","year":"2013","journal-title":"Immunology"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3702","article-title":"KAT6B is a tumor suppressor histone H3 lysine 23 acetyltransferase undergoing genomic loss in small cell lung cancer","volume":"75","author":"Sim\u00f3-Riudalbas","year":"2015","journal-title":"Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2024.101901","article-title":"An evaluation of genetic predisposition to congenital anomalies and pediatric cancer supports KAT6B as a novel neuroblastoma susceptibility gene","volume":"3","author":"Gu","year":"2025","journal-title":"Genet Med Open"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1300490110","article-title":"MOZ increases p53 acetylation and premature senescence through its complex formation with PML","volume":"110","author":"Rokudai","year":"2013","journal-title":"PNAS"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-023-01320-7","article-title":"Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition","volume":"19","author":"Bishop","year":"2023","journal-title":"Nat Chem Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1961903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:19:03Z","timestamp":1791285543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1961903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":136,"alternative-id":["10.3389\/fimmu.2026.1961903"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1961903","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1961903"}}